November 14, 2019 8:23am

… After three (3) down sessions this week for a November aggregate of five (5) negative and four (4) positive closes in the cell and gene therapy companies

News: Athersys (ATHX) and its collaborator in Japan, Healios received notification this week from the Pharmaceutical Affairs and Food Sanitation Council (PAFSC) that its acute respiratory distress syndrome (ARDS) clinical program using HLCM051 (MultiStem® Cell Therapy),  receiving orphan regenerative medicine designation from the Ministry of Health, Labour and Welfare within the next few weeks.

How does the old Ben Graham quote go? "In the short run, the market is a voting machine but in the long run it is a weighing machine"? 


My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will with the headline and what could happen today


Dow futures are DOWN -0.12% (-32 points), S&P futures are DOWN -0.14% (-4 points) and NASDAQ futures are DOWN -0.19% (-16 points)


US futures are projected lower;

European stocks traded slightly lower as trade negotiations between the U.S. and China are understood to have hit a roadblock as the pan-European Stoxx 600 edged -0.2%;

Asia Pacific markets are mixed as China's October industrial production data missed forecasts;


Data Docket: the latest weekly jobless claims will be released at around 8:30 a.m. ET. The Labor Department is poised to report its producer price index (PPI) for October at the same time.



Today’s anxiety is largely attuned to global trade developments, as investors want progress and are anxious about any deal if any about the world’s two largest economies.

U.S. and China are at a reported impasse as they seek to finalize a limited trade agreement amid a tariff war that has lasted for more than a year.

Washington and Beijing have imposed tariffs on billions of dollars’ worth of one another’s goods since the start of 2018, battering financial markets and souring business and consumer sentiment <CNBC>.

Chinese industrial production data for October missed forecasts, growing 4.7% year-on-year, Reuters reported citing official data. That compared against expectations of a 5.4% growth from a Reuters poll.


I get to pick - cautiously amongst the clutter of the oversold!


Wednesday night’s newsletter heading: “low volume is a factor as the sector’s bottom kisses the floor, again

Last night’s numbers:

  • The NASDAQ closed DOWN -3.99 points (-0.05%);
  • The IBB closed up +0.20% while the XBI closed up +0.27%;
  • The close was negative with an Advance/Decline line of 12/29, 1 flat, 1 reversed merged (HSGX) and 2 acquired;
  • The range of the 12 upside was +0.09% (EDIT) to +7.31% (KOOL +0.39) while the  29 downside ranged from -0.01% (RENE.L) to -16.94% (CUR);
  • 0 out of the 12 upside had higher than the 3 month average volume;
  • 0 out of the 29 downside had higher than the 3 month average volume;

Review the context of Q4’s market – so far:

  • November has registered 4 positive and 5 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;


Companies in my headlights – It’s your decision; I provide an idea and context:

*** I’m looking at SELLING:

  • CRISPR Therapeutics (CRSP +$0.21 after Tuesday’s +$2.67, Monday’s +$0.37, Friday’s +$1.53, Thursday’s +$1.18 and last Wednesday’s +$1.23 – a lot of upside that could be sold into;

Considering BUYING:

  • Athersys (ATHX) on the basis of its partner’s Healios’ news (in title)
  • Sage Therapeutics (SAGE -$1.89 after Tuesday’s -$2.79, Monday’s -$2.06, Friday’s +$7.47, Thursday’s -$0.67 and last Wednesday’s -$5.73) – on a rotational basis;



Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.